U.S. Markets closed

Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $197,800 of Shares

President & CEO of Esperion Therapeutics Inc (30-Year Financial, Insider Trades) Timothy M Mayleben (insider trades) bought 5,000 shares of ESPR on 08/01/2019 at an average price of $39.56 a share. The total cost of this purchase was $197,800.

Esperion Therapeutics Inc is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C, lowering therapies for the treatment of patients with elevated LDL-C. Esperion Therapeutics Inc has a market cap of $1.04 billion; its shares were traded at around $38.67 with and P/S ratio of 7.56. Esperion Therapeutics Inc had annual average EBITDA growth of 8.90% over the past ten years. GuruFocus has detected 2 severe warning signs with Esperion Therapeutics Inc. .

CEO Recent Trades:

  • President & CEO Timothy M Mayleben bought 5,000 shares of ESPR stock on 08/01/2019 at the average price of $39.56. The price of the stock has decreased by 2.25% since.

Directors and Officers Recent Trades:

  • 10% Owner Target N V Biotech bought 50,000 shares of ESPR stock on 07/23/2019 at the average price of $42.65. The price of the stock has decreased by 9.33% since.

For the complete insider trading history of ESPR, click here

.This article first appeared on GuruFocus.